Suárez, C.; Vieito, M.; Valdivia, A.; González, M.; Carles, J.
Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors. Med. Sci. 2023, 11, 46.
https://doi.org/10.3390/medsci11030046
AMA Style
Suárez C, Vieito M, Valdivia A, González M, Carles J.
Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors. Medical Sciences. 2023; 11(3):46.
https://doi.org/10.3390/medsci11030046
Chicago/Turabian Style
Suárez, Cristina, Maria Vieito, Augusto Valdivia, Macarena González, and Joan Carles.
2023. "Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors" Medical Sciences 11, no. 3: 46.
https://doi.org/10.3390/medsci11030046
APA Style
Suárez, C., Vieito, M., Valdivia, A., González, M., & Carles, J.
(2023). Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors. Medical Sciences, 11(3), 46.
https://doi.org/10.3390/medsci11030046